Possible rhabdomyolysis secondary to severe dyskinesias or NMS in patients w/ Parkinson's disease; slowly w/draw entacapone & other dopaminergics when considered necessary; if signs &/or symptoms [eg, motor symptoms (rigidity, myoclonus, tremor), mental status changes (eg, agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile BP) & elevated serum creatine phosphokinase] occur despite slow entacapone w/drawal, increased levodopa dosage may be necessary. Patients w/ ischemic heart disease. May aggravate levodopa-induced orthostatic hypotension. Follow-up of wt in patients experiencing diarrhoea to avoid potential excessive decreased wt. Discontinue use & consider appropriate medical therapy & investigation for colitis in the event of prolonged or persistent diarrhoea. Regularly monitor for development of impluse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge & compulsive eating. Perform general medical evaluation including liver function to patients who experience progressive anorexia, asthenia & decreased wt. Concomitant use w/ catechol-O-methyl transferase (COMT)-metabolised medicinal products (eg, rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, α-methyldopa & apomorphine); medicinal products causing orthostatic hypotension; dopamine agonists (eg, bromocriptine), selegiline or amantadine. Possible somnolence & sudden sleep onset episodes in patients w/ Parkinson's disease. May cause dizziness & symptomatic orthostatism; caution should be exercised when driving or using machines. May consider a longer dosing interval in patients receiving dialysis. Not to be used during pregnancy. Advise women not to breastfeed during treatment. Childn <18 yr.
Sign Out
